Clinical Characteristics, Cardiometabolic Risk Burden and Therapeutic Patterns in Patients Attending Cardiology Clinics in Spain: The RIESCAR Study

Loading...
Thumbnail Image

Identifiers

Publication date

Authors

Cosín-Sales, Juan
Campuzano Ruiz, Raquel
Cequier, Ángel
Díez-Villanueva, Pablo
Aldomà-Balasch, Albina
Arrate-Esteban, Vicente Ignacio
López-Sánchez, Eduardo Sebastián
Gómez-Pajuelo, Casimiro
Fernández-Friera, Leticia
Chopo-Alcubilla, José Miguel

Advisors

Other responsabilities

Journal Title

Bibliographic citation

Cosín-Sales J, Campuzano R, Cequier A, Díez-Villanueva P, Aldomà-Balasch A, Arrarte-Esteban VI, López-Sánchez ES, Gómez-Pajuelo C, Fernández-Friera L, Chopo-Alcubilla JM, Muñiz J, Gómez-Doblas JJ; RIESCAR Study Investigators. Clinical characteristics, cardiometabolic risk burden and therapeutic patterns in patients attending cardiology clinics in Spain: the RIESCAR study. J Clin Med. 2026 Oct 14;15(20):7916.

Type of academic work

Academic degree

Abstract

[Abstract] Background/Objectives: Contemporary data on patients attending cardiology outpatient clinics in Spain are scarce. We aimed to characterise cardiovascular conditions, cardiometabolic burden, risk-factor control and treatment patterns. Methods: RIESCAR is a national, multicentre, observational study. This analysis included 2808 adults evaluated in 50 general cardiology outpatient clinics. Results: Hypertension was present in 60.3%, dyslipidaemia in 58.9%, type 2 diabetes mellitus in 24.7%, obesity in 32.4%, and central obesity in 48.7%. Established cardiovascular disease was documented in 59.7%, with coronary artery disease (30.0%), atrial fibrillation (18.2%) and heart failure (11.7%) being the most frequent conditions. Among hypertensive patients, 42.6% had blood pressure ≥ 140/90 mmHg. In patients with established atherosclerotic cardiovascular disease (ASCVD), 37.2% achieved LDL-C < 55 mg/dL. Patients received a high number of cardiovascular drugs (mean 3.9). Among patients with a potential clinical indication for contemporary cardiometabolic therapies, SGLT2 inhibitors and GLP-1 receptor agonists were used in 35.4% and 8.6%, respectively. Conclusions: Patients attending cardiology clinics in Spain have a high cardiometabolic burden, with important gaps in blood-pressure and LDL-C target attainment. Use of contemporary cardiometabolic therapies remains variable, highlighting opportunities to strengthen cardiovascular prevention in routine practice.

Description

Rights

Attribution 4.0 International
Attribution 4.0 International

Except where otherwise noted, this item's license is described as Attribution 4.0 International